Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb;72(2):e13062.
doi: 10.1111/ijcp.13062. Epub 2018 Jan 30.

Current Evidence for the Treatment of Hypothyroidism With Levothyroxine/Levotriiodothyronine Combination Therapy Versus Levothyroxine Monotherapy

Free PMC article

Current Evidence for the Treatment of Hypothyroidism With Levothyroxine/Levotriiodothyronine Combination Therapy Versus Levothyroxine Monotherapy

James V Hennessey et al. Int J Clin Pract. .
Free PMC article


Objective: Hypothyroidism is relatively common, occurring in approximately 5% of the general US population aged ≥12 years. Levothyroxine (LT4) monotherapy is the standard of care. Approximately, 5%-10% of patients who normalise thyroid-stimulating hormone levels with LT4 monotherapy may have persistent symptoms that patients and clinicians may attribute to hypothyroidism. A long-standing debate in the literature is whether addition of levotriiodothyronine (LT3) to LT4 will ameliorate lingering symptoms. Here, we explore the evidence for and against LT4/LT3 combination therapy as the optimal approach to treat euthyroid patients with persistent complaints.

Methods: Recent literature indexed on PubMed was searched in March 2017 using the terms "hypothyroid" or "hypothyroidism" and "triiodothyronine combination" or "T3 combination." Relevant non-review articles published in English during the past 10 years were included and supplemented with articles already known to the authors.

Findings: Current clinical evidence is not sufficiently strong to support LT4/LT3 combination therapy in patients with hypothyroidism. Polymorphisms in deiodinase genes that encode the enzymes that convert T4 to T3 in the periphery may provide potential mechanisms underlying unsatisfactory treatment results with LT4 monotherapy. However, results of studies on the effect of LT4/LT3 therapy on clinical symptoms and thyroid-responsive genes have thus far not been conclusive.

Conclusions: Persistent symptoms in patients who are biochemically euthyroid with LT4 monotherapy may be caused by several other conditions unrelated to thyroid function, and their cause should be aggressively investigated by the clinician.

Similar articles

See all similar articles

Cited by 9 articles

See all "Cited by" articles


    1. Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012;18:988‐1028. - PubMed
    1. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87:489‐499. - PubMed
    1. Garmendia Madariaga A, Santos Palacios S, Guillen‐Grima F, Galofre JC. The incidence and prevalence of thyroid dysfunction in Europe: a meta‐analysis. J Clin Endocrinol Metab. 2014;99:923‐931. - PubMed
    1. Waring AC, Arnold AM, Newman AB, et al. Longitudinal changes in thyroid function in the oldest old and survival: the Cardiovascular Health Study All‐Stars Study. J Clin Endocrinol Metab. 2012;97:3944‐3950. - PMC - PubMed
    1. Braverman LE, Cooper DS. Werner & Ingbar's The Thyroid: A Fundamental and Clinical Text, 10th ed Philadelphia, PA: Lippincott Williams & Wilkins; 2013.

MeSH terms